|
|
- 2015
重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白抑制强直性脊柱炎趋化因子CXCL16及其受体CXCR6的表达
|
Abstract:
| [1] | 赵伟,黄烽.细胞核因子κB受体活化因子配基在强直性脊柱炎的表达及意义[J].解放军医学杂志, 2004, 29(6):482-485. ZHAO Wei, HUANG Feng. The role of RANKL in the pathogenesis of peripheral joint bone destruction in ankylosing spondylitis[J]. Medical Journal of Chinese People's Liberation Army, 2004, 29(6):482-485. |
| [2] | 徐愿,阎小萍,张文健.补肾强督方含药血清对强直性脊柱炎OPG/RANKL通路的作用[J].中国中西医结合杂志, 2012, 32(4):521-524. XU Yuan, YAN Xiaoping, ZHANG Wenjian. The function of bushen qiangdu recipe containing serum in OPG/RANKL pathway of ankylosing spondylitis patients[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32(4):521-524. |
| [3] | 庄宇,简怡娜,谭志明.趋化因子CXCL16与系统性红斑狼疮的研究进展[J].中外医学研究, 2012, 10(6):146-148. ZHUANG Yu, JIAN Yina, TAN Zhiming. The research progress of chemolines CXCL16 and systemic lupus erythematosus[J]. Chinese and Foreign Medical Research, 2012, 10(6):146-148. |
| [4] | Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, et al. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis[J]. Patient Preference and Adherence, 2013, 7:961-972. |
| [5] | Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook:a guide to assess spondyloarthritis[J]. Ann Rheum Dis, 2009, 68:Suppl 2:ii1-44.. doi:10.1136/ard.2008.104018. |
| [6] | Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand[J]. Nature, 1999, 402(6759):304-309. |
| [7] | La Porta CA. Thoughts about cancer stem cells in solid tumors[J]. World J Stem Cells, 2012, 4(3):17-20. |
| [8] | Kawai T, Matsuyama T, Hosokawa Y, et al. B and T Lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease[J]. American Journal of Pathology, 2006, 169(3):987-998. |
| [9] | Baraliakos X, Brmdt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept:clinical and magnetic resonance imaging data[J]. Arthritis Rheum, 2005, 53(6):856-863. |
| [10] | Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25mg twice-weekly[J]. Rheumatology, 2007, 46(6):999-1004. |
| [11] | Lee SH, Lee YA, Hong SJ, et al. Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean Patients[J]. Clin Rheumatol, 2008, 27(2):179-181. |
| [12] | Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general[J]. Ann Rheum Dis, 2011, 70(1):25-31. |
| [13] | Chen CH, Chen HA, Liao HT, et al. Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis:OPG is associated with poor physical mobility and reflects systemic inflammation[J]. Clin Rheumatol, 2010, 29(10):1155-1161. |
| [14] | Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-κB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis[J]. Rheumatology, 2006, 45(10):1197-1200. |
| [15] | Yilmaz S, Cinar M, Pekel A, et al. The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behcet's disease[J]. Clin Exp Rheumatol, 2013, 31(3 suppl 77):84-87. |
| [16] | Lee J, Noh JW, Hwang JW, et al. Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis:a retrospective analysis[J]. Clin Rheumatol, 2010, 29(10):1149-1154. |
